BACKGROUND/AIMS: HO-1 and EETs are functionally linked and their interactions influence body weight, insulin sensitivity, and serum levels of inflammatory cytokines in metabolic syndrome phenotype of HO-2 null mice. The HO-2 isozyme is essential for regulating physiological levels of ROS. Recent studies have suggested a potential role of EET in modifying adipocyte differentiation through up-regulation of HO-1-adiponectin-AkT signaling in human mesenchymal stem cells (MSCs). Our aim was to examine the consequences of HO deficiency on MSC-derived adipogenesis in vitro using MSC derived from HO-2 null and WT mice in vivo. METHODS: Four-month-old HO-2 null (HO-2(-/-)) and B6/129SF2/J (WT) mice were divided into three groups (four mice/group): WT, HO-2(-/-), and HO-2(-/-) +CoPP. Adipogenesis was performed on purified MSC-derived adipocytes cultured in adipogenic differentiation media and an EET-agonist was added every 3 days. RESULTS: HO-2 depletion of MSC adipocytes resulted in increased adipogenesis (p<0.01) and increased levels of inflammatory cytokines including (TNF)-alpha (p<0.05), (MCP)-1 (p<0.05), and (IL-1)-beta (p<0.05). These results were accompanied by decreases in HO-1 (p<0.05) and subsequently EET and HO activity (p<0.05). Up-regulation of HO-1 resulted in decreased MSC-derived adipocyte differentiation, decreased production of TNF-alpha and MCP-1 and increased levels of adiponectin (p<0.05). Cyp2J5 (p<0.05), HO-1 (p<0.05), and adiponectin mRNA levels (p<0.05) were also decreased in visceral adipose tissue isolated from HO-2 null compared to WT mice. EET agonist stimulation of MSC adipocytes derived from HO-2 null mice yielded similar results. CONCLUSION: Increased levels of EET and HO-1 are essential for protection against the adverse effects of adipocyte hypertrophy and the ensuing metabolic syndrome. These results offer a portal into therapeutic approaches for the prevention of the metabolic syndrome.
BACKGROUND/AIMS: HO-1 and EETs are functionally linked and their interactions influence body weight, insulin sensitivity, and serum levels of inflammatory cytokines in metabolic syndrome phenotype of HO-2 null mice. The HO-2 isozyme is essential for regulating physiological levels of ROS. Recent studies have suggested a potential role of EET in modifying adipocyte differentiation through up-regulation of HO-1-adiponectin-AkT signaling in human mesenchymal stem cells (MSCs). Our aim was to examine the consequences of HO deficiency on MSC-derived adipogenesis in vitro using MSC derived from HO-2 null and WT mice in vivo. METHODS: Four-month-old HO-2 null (HO-2(-/-)) and B6/129SF2/J (WT) mice were divided into three groups (four mice/group): WT, HO-2(-/-), and HO-2(-/-) +CoPP. Adipogenesis was performed on purified MSC-derived adipocytes cultured in adipogenic differentiation media and an EET-agonist was added every 3 days. RESULTS:HO-2 depletion of MSC adipocytes resulted in increased adipogenesis (p<0.01) and increased levels of inflammatory cytokines including (TNF)-alpha (p<0.05), (MCP)-1 (p<0.05), and (IL-1)-beta (p<0.05). These results were accompanied by decreases in HO-1 (p<0.05) and subsequently EET and HO activity (p<0.05). Up-regulation of HO-1 resulted in decreased MSC-derived adipocyte differentiation, decreased production of TNF-alpha and MCP-1 and increased levels of adiponectin (p<0.05). Cyp2J5 (p<0.05), HO-1 (p<0.05), and adiponectin mRNA levels (p<0.05) were also decreased in visceral adipose tissue isolated from HO-2 null compared to WT mice. EET agonist stimulation of MSC adipocytes derived from HO-2 null mice yielded similar results. CONCLUSION: Increased levels of EET and HO-1 are essential for protection against the adverse effects of adipocyte hypertrophy and the ensuing metabolic syndrome. These results offer a portal into therapeutic approaches for the prevention of the metabolic syndrome.
Authors: Angela Burgess; Ming Li; Luca Vanella; Dong Hyun Kim; Rita Rezzani; Luigi Rodella; Komal Sodhi; Martina Canestraro; Pavel Martasek; Stephen J Peterson; Attallah Kappas; Nader G Abraham Journal: Hypertension Date: 2010-11-01 Impact factor: 10.190
Authors: David Sacerdoti; Claudia Colombrita; Marco Di Pascoli; Michal L Schwartzman; Massimo Bolognesi; John R Falck; Angelo Gatta; Nader G Abraham Journal: Prostaglandins Other Lipid Mediat Date: 2006-08-30 Impact factor: 3.072
Authors: George S Drummond; Jeffrey Baum; Menachem Greenberg; David Lewis; Nader G Abraham Journal: Arch Biochem Biophys Date: 2019-08-16 Impact factor: 4.013
Authors: Luca Vanella; Giovanni Li Volti; Salvatore Guccione; Giancarlo Rappazzo; Eliana Salvo; Morena Pappalardo; Stefano Forte; Michal L Schwartzman; Nader G Abraham Journal: Biochem Biophys Res Commun Date: 2013-02-21 Impact factor: 3.575
Authors: James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song Journal: Adv Pharmacol Date: 2013
Authors: Shailendra P Singh; Joseph Schragenheim; Jian Cao; John R Falck; Nader G Abraham; Lars Bellner Journal: Prostaglandins Other Lipid Mediat Date: 2016-07-11 Impact factor: 3.072
Authors: John A McClung; Lior Levy; Victor Garcia; David E Stec; Stephen J Peterson; Nader G Abraham Journal: Pharmacol Ther Date: 2021-09-06 Impact factor: 12.310
Authors: Maayan Waldman; Lars Bellner; Luca Vanella; Joseph Schragenheim; Komal Sodhi; Shailendra P Singh; Daohong Lin; Anand Lakhkar; Jiangwei Li; Edith Hochhauser; Michael Arad; Zbigniew Darzynkiewicz; Atallah Kappas; Nader G Abraham Journal: Stem Cells Dev Date: 2016-06-27 Impact factor: 3.272
Authors: Weibin Zha; Matthew L Edin; Kimberly C Vendrov; Robert N Schuck; Fred B Lih; Jawahar Lal Jat; J Alyce Bradbury; Laura M DeGraff; Kunjie Hua; Kenneth B Tomer; John R Falck; Darryl C Zeldin; Craig R Lee Journal: J Lipid Res Date: 2014-08-11 Impact factor: 5.922